TickerFacts.

Vertex Pharmaceuticals Inc (VRTX): R&D Expense

Annual figures by period end, from SEC filings.

$3.91B
Year ended 2025-12-31
$3.91B
Trailing 12 months to 2026-06-30
+15.5%
3-year compound annual growth
+18.9%
5-year compound annual growth
2020-12-31: $1.64B2021-12-31: $1.94B2022-12-31: $2.54B2023-12-31: $3.16B2024-12-31: $3.63B2025-12-31: $3.91B$3.91B
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$3.91B+7.7%2026-02-13, From 2025-01-01
2024-12-31$3.63B+14.8%2026-02-13, From 2024-01-01
2023-12-31$3.16B+24.5%2026-02-13, From 2023-01-01
2022-12-31$2.54B+31.1%2025-02-13, From 2022-01-01
2021-12-31$1.94B+17.8%2024-02-15, From 2021-01-01
2020-12-31$1.64Bn/a2023-02-10, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Vertex Pharmaceuticals Inc (VRTX)2025-12-31$3.91B+7.7%
Bausch Health Companies Inc. (BHC)2025-12-31$629.00M+2.1%
Viatris Inc (VTRS)2025-12-31$965.90M+19.4%
Regeneron Pharmaceuticals, Inc. (REGN)2025-12-31$5.85B+14.0%
Zoetis Inc. (ZTS)2025-12-31$698.00M+1.7%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$1.01B+1.5%
Organon & Co. (OGN)2025-12-31$366.00M-22.0%
BeOne Medicines Ltd. (ONC)2025-12-31$2.15B+9.9%
Elanco Animal Health Inc (ELAN)2025-12-31$368.00M+7.0%

Compare VRTX, BHC, VTRS, REGN side by side · Screen every company in Pharmaceutical Preparations ↗